依沃西单抗联合化疗用于EGFR-TKIs治疗后缓慢进展的晚期非小细胞肺癌的临床观察
x

请在关注微信后,向客服人员索取文件
| 篇名: | 依沃西单抗联合化疗用于EGFR-TKIs治疗后缓慢进展的晚期非小细胞肺癌的临床观察 |
| TITLE: | Clinical observation of ivonescimab plus chemotherapy in advanced non-small cell lung cancer with slow progression after EGFR-TKIs treatment |
| 摘要: | 目的 探索依沃西单抗联合化疗(卡铂+培美曲塞)方案在表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKIs)治疗后缓慢进展的晚期非小细胞肺癌(NSCLC)中的效果及安全性。方法回顾性选取2024年6月1日至12月31日于宁波大学附属李惠利医院就诊的经EGFR-TKIs治疗后缓慢进展的晚期NSCLC患者117例为研究对象,按照患者的治疗方案分为对照组(继续采用原EGFR-TKIs+培美曲塞方案,n=61)和观察组(采用依沃西单抗+卡铂+培美曲塞方案,n=56)。两组患者均至少接受4个周期治疗,每3周为1个周期;随访截至2025年12月31日。对比两组患者首次疗效评估情况(于治疗2个周期后进行)、随访期内无进展生存期(PFS)和总生存期(OS),以及治疗期间发生的不良反应;同时按EGFRT790M突变状态、肝转移、脑转移及原EGFR-TKIs种类等进行亚组治疗效应及交互作用分析。结果观察组患者的客观缓解率(ORR)为26.79%,显著高于对照组的9.84%(P<0.05);观察组与对照组的疾病控制率(DCR)分别为94.64%和93.44%,差异无统计学意义(P>0.05)。对照组患者的中位PFS为7.16(5.22,8.88)个月,观察组为8.13(5.91,9.47)个月,观察组显著长于对照组(P<0.05)。对照组患者的中位OS为14.67(9.66,15.92)个月,观察组为14.21(11.02,16.52)个月,两组对比差异无统计学意义(P>0.05)。亚组分析结果显示,在EGFRT790M突变、存在肝转移、存在脑转移及使用吉非替尼的患者中,观察组方案较对照组方案出现疾病进展的风险更低(P<0.05)。观察组患者的1~2级、3~4级白细胞减少、中性粒细胞减少、血小板减少、贫血及恶心呕吐的发生率,以及1~2级纳差乏力、淀粉酶升高及血脂异常的发生率均显著高于对照组(P<0.05)。结论与缓慢进展前所用EGFR-TKIs联合培美曲塞方案相比,依沃西单抗联合化疗方案与更高的ORR和更长的PFS相关,但未显示明确的OS或DCR优势。EGFRT790M突变阳性、存在肝转移、存在脑转移及缓慢进展前使用吉非替尼的患者上述PFS效应差异可能更明显。 |
| ABSTRACT: | OBJECTIVE To explore the efficacy and safety of the ivonescimab plus chemotherapy (carboplatin+pemetrexed) regimen in patients with advanced non-small cell lung cancer (NSCLC) with slow progression after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) treatment.METHODS A total of 117 patients with advanced NSCLC who experienced slow progression after EGFR-TKIs treatment were retrospectively enrolled at Ningbo Medical Center Li Huili Hospital from June 1, 2024, to December 31, 2024. Based on the treatment regimen, they were divided into a control group (continued prior EGFR-TKIs+pemetrexed, n =61) and an observation group (ivonescimab+carboplatin+pemetrexed, n =56). Both groups received at least four treatment cycles, with each cycle lasting three weeks. The follow-up cutoff date was December 31, 2025. The first efficacy assessment (performed after two treatment cycles), progression-free survival (PFS) and overall survival (OS) during follow-up, adverse reactions during treatment, and subgroup treatment effects and interaction effects according to EGFR T790M mutation status, liver metastasis, brain metastasis, and prior EGFR-TKIs type were compared between the two groups.RESULTS The objective response rate (ORR) was significantly higher in the observation group than in the control group (26.79% vs. 9.84%, P <0.05). The disease control rate (DCR) was 94.64% in the observation group and 93.44% in the control group, with no statistically significant difference ( P >0.05). Median PFS was 7.16 (5.22, 8.88) months in the control group and 8.13 (5.91, 9.47) months in the observation group, with the observation group significantly longer than the control group ( P <0.05). Median OS was 14.67 (9.66, 15.92) months in the control group and 14.21 (11.02, 16.52) months in the observation group, with no statistically significant difference between the two groups ( P >0.05). Subgroup analysis showed that in patients with EGFR T790M mutation, liver metastasis, brain metastasis, or gefitinib treatment, the observation group regimen was associated with a lower risk of disease progression than the control group regimen ( P <0.05). The incidences of grade 1-2 and grade 3-4 of leukopenia, neutropenia, thrombocytopenia, anemia, and nausea/vomiting, as well as grade 1-2 of anorexia/fatigue, elevated amylase, and dyslipidemia, were significantly higher in the observation group than in the control group ( P <0.05).CONCLUSIONS Compared with prior EGFR-TKIs plus pemetrexed regimen, ivonescimab plus chemotherapy (carboplatin+pemetrexed) regimen was associated with a higher ORR and longer PFS, with no statistically significant differences in OS or DCR. Patients with EGFR T790M mutation-positive status, liver metastasis, brain metastasis, or prior gefitinib treatment before slow progression may show a more pronounced PFS effect as described above. |
| 期刊: | 2026年第37卷第21期 |
| 作者: | 童晶涛;史亚杰;章慧;王春玲;徐国栋;陈伟庄 |
| AUTHORS: | TONG Jingtao,SHI Yajie,ZHANG Hui,WANG Chunling,XU Guodong,CHEN Weizhuang |
| 关键字: | 依沃西单抗;化疗;表皮生长因子受体-酪氨酸激酶抑制剂;非小细胞肺癌;缓慢进展 |
| KEYWORDS: | ivonescimab;Chemotherapy;EGFR-TKIs;non-small cell lung cancer;slow progression |
| 阅读数: | 2 次 |
| 本月下载数: | 0 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!
返回
加入收藏










